Complementary Models of Cardiometabolic Stress Reveal Conserved Molecular Programs Driving Cardiac Remodeling

  • bioRxiv. 2026 Aug 31:2026.08.28.747839. doi: 10.64898/2026.08.28.747839.
Maaria Saeed  1 ,  Hyun-Jung Jung  1 ,  Bo Ryung Lee  1 ,  Swapna Patil  1 ,  Ripon Sarkar  1 ,  Connor Lantz  2 ,  Mi Jeong Heo  1 ,  Alexandra Serrato  1 ,  Yu A An  1 ,  Kang Ho Kim  1 ,  Matthew DeBerge  1
Affiliations
  • 1. Department of Anesthesiology, Critical Care and Pain Medicine, University of Texas Health Science Center, Houston.
  • 2. Comprehensive Transplant Center, Department of Surgery, Feinberg School of Medicine, Northwestern University, Chicago.
Abstract

Background: Cardiometabolic diseases frequently involve concurrent cardiovascular and hepatic dysfunction, yet the conserved molecular mechanisms underlying these systemic responses remain poorly defined.

Objectives: To identify conserved molecular responses across complementary manifestations of cardiometabolic stress and determine whether integrated multi-organ analyses reveal therapeutically actionable targets for Heart Failure.

Methods: Cardiac functional phenotyping, hepatic injury profiling, and bulk RNA Sequencing were performed across three complementary mouse models representing distinct manifestations of cardiometabolic stress: high-fat diet plus L-NAME (HFD+LN)-induced Heart Failure with preserved ejection fraction (HFpEF; Cardiovascular Disease), Western diet (WD)-induced Obesity (systemic metabolic stress), and choline-deficient, L-amino acid-defined, high-fat diet (CDAHFD)-induced steatotic Liver Disease (hepatic metabolic stress). Comparative transcriptomic analyses distinguished organ-specific responses from conserved molecular signatures.

Results: Each model produced distinct systemic, hepatic, and cardiac phenotypes accompanied by divergent transcriptional responses within individual organs. Cross-model and cross-organ integration identified a limited set of conserved molecular responses to cardiometabolic stress, with Serpine1, encoding plasminogen activator inhibitor-1 (PAI-1), emerging as a highly conserved candidate that exhibited preferential induction in the heart. Pharmacologic inhibition of PAI-1 significantly improved cardiac function and attenuated adverse remodeling in established HFpEF, whereas hepatic pathology was comparatively less affected, indicating differential organ-specific dependence on this pathway.

Conclusions: Integrated analyses across complementary manifestations of cardiometabolic stress identified conserved molecular signatures that transcend individual disease models and organs. These findings establish a comparative framework for discovering cardiovascular therapeutic targets and identify PAI-1 as a promising mediator of cardiac remodeling in HFpEF.

Products